SMS Reminders to Strengthen Demand for HPV Vaccination in Georgia
8. september 2022 oppdatert av: The Behavioural Insights Team
Design, Test and Evaluate Behavioural Insights Interventions to Strengthen Demand for Immunisation in Georgia
It is possible that achieving adequate HPV vaccination coverage will allow cervical cancer to be virtually eliminated. This is a priority for Georgia, where the burden of mortality and morbidity from cervical cancer is high and the yearly prevalence of cervical cancer is 14.5 per 100,000 population.
The objective of the intervention evaluated is to increase the uptake of the 1st dose of the HPV vaccination in Georgia. The intervention aims to achieve this by providing a SMS reminder informed by behavioural insights (BI) to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination, share information about the vaccine, and encourage them to book an appointment to receive the vaccination. Four different SMS messages will be compared to no SMS message.
The evaluation will be a 5-arm randomised controlled trial (RCT) which aims to answer the research question: Does each of the designed BI-informed SMS reminders increase the uptake of the first dose of the HPV vaccination among eligible girls in Georgia, compared to no reminder? Our hypothesis is that SMS reminders will increase the uptake of HPV vaccination.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Forventet)
55176
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Clement Bisserbe
- Telefonnummer: +254711375983
- E-post: clement.bisserbe@bi.team
Studer Kontakt Backup
- Navn: Zara Y Goozee
- Telefonnummer: +447709105143
- E-post: zara.goozee@bi.team
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
10 år til 12 år (Barn)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Girls
- Aged 10-12 years
- Not yet received any doses of the HPV vaccine
- With a caregiver's mobile phone number in the e-health system.
Exclusion Criteria:
- Boys
- Girls aged less than 10 or more than 12 years
- Girls with no caregiver phone number in the e-health system
- Girls who have received 1 or 2 doses of the HPV vaccine
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: No SMS reminder
This group will receive no reminder
|
|
|
Eksperimentell: Short SMS with no additional information
Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: "As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer.
Contact your family doctor today to arrange an appointment."
|
A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
|
|
Eksperimentell: Short SMS + NCDC link
Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: "As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer.
Contact your family doctor today to arrange an appointment.
More information on the official NCDC website"
|
A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
|
|
Eksperimentell: SMS with "reserved for her" framing + NCDC link
Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: "As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer.
Her vaccine is reserved at the policlinic.
Contact your family doctor today to arrange an appointment.
More information on the official NCDC website"
|
A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
|
|
Eksperimentell: SMS with safety information + NCDC link
Caregivers of girls eligible to receive the HPV vaccination in this group will receive an SMS reminder that states: "As per national immunization calendar your daughter is due her free human papilloma virus vaccine, which will protect her against cervical cancer.
The vaccine has been given safely to more than 118 million girls worldwide.
Contact your family doctor today to arrange an appointment.
More information on the official NCDC website"
|
A BI-informed SMS reminder to remind caregivers of girls between 10-12 years that their daughter is due the first dose of her HPV vaccination and share information about the vaccine.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
HPV vaccination status
Tidsramme: At 60 days after receiving the SMS reminder
|
1st dose HPV vaccination status of the caregiver's daughter
|
At 60 days after receiving the SMS reminder
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Hannah Behrendt, Behavioural Insights Team
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
13. september 2022
Primær fullføring (Forventet)
12. november 2022
Studiet fullført (Forventet)
12. november 2022
Datoer for studieregistrering
Først innsendt
8. september 2022
Først innsendt som oppfylte QC-kriteriene
8. september 2022
Først lagt ut (Faktiske)
13. september 2022
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
13. september 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. september 2022
Sist bekreftet
1. september 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UNICEF Georgia 2020021
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
No individual data will be shared from the e-health modules of the National Center for Disease Control and Public Health of Georgia and Information Technology Agency.
All data shared will be anonymised for analysis and aggregated for reporting, there is no risk of participant identification.
Data will include HPV vaccination status, the version of the SMS reminder received, and age.
The data will not include information on patients' names, addresses, location, ethnicity, phone numbers, or any information on medical conditions.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .